loader
Please Wait
Applying Filters...

Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    List of Certificates of Suitability (CEPs) for cep_2017_214___rev_01 Active Pharmaceutical Ingredient (API) issued by the EDQM. Original Data: EDQM Database

    Client Virtual Booth
    Menu

    Allessa GmbH

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PharmaCompass

    Inke S.A: APIs manufacturing plant.

    Send me more info on How To Grow My Business Digitally?

    Left Arrow
    Right Arrow
    Filters Filter
    Cross PopUp
    FILTER :

    filter

    01 ALLESSA GMBH FRANKFURT DE (1)

    filter

    01 Molsidomine (1)

    filter

    01 Germany (1)

    filter

    01 Valid (1)

    ListList of Suppliers
    refresh Reset Filter
    refresh Reset Filter
    product-page Supplier Virtual Booth
    price-trend Ask Us

    ALLESSA GMBH FRANKFURT DE

    Contact Supplier
      Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
      Post an Enquiry Post an Enquiry
      Flag Germany
      Virtual Booth Virtual Booth
      Digital Content Digital Content

      Molsidomine

      PDF Supplier PDF
      URL Supplier Web Content
      CEP 2017-214 - Rev 01
      Valid
      Chemical
      2024-01-05
      1701
      ASK
      US
      PHARMACOMPASS
      Upload
      your Marketing & Sales content

      Looking for Certificates of Suitability (CEPs) for CEP 2017-214 - Rev 01 of Allessa Gmbh Frankfurt De

      Looking for Certificates of Suitability (CEPs) for CEP 2017-214 - Rev 01 of Allessa Gmbh Frankfurt De 1

      20

      Allessa Gmbh Frankfurt De, based in Germany, is a pharmaceutical company.

      One of their significant offerings is Molsidomine, supported by a 'Valid' Certificate of Suitability (CEP) with the number CEP 2017-214 - Rev 01

      This Chemical Type CEP, issued on January 05, 2024, remains in force until January 01, 1970, ensuring its reliability within the pharmaceutical industry.

      Substance Number 1701 associated with this CEP further emphasizes

      Post Enquiry
      POST ENQUIRY